Impact of statin therapy on plasma leptin concentrations: a systematic review and meta‐analysis of randomized placebo‐controlled trials

Sahebkar, Amirhossein; Giua, Renato; Pedone, Claudio

doi:10.1111/bcp.13086

Cited by 20 publications

(14 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They showed that simvastatin and simvastatin plus ezetimibe combination decreased the levels of adipokines. On the other hand, in a meta-analysis, statin therapy failed to show favorable effects on the leptin levels (42). Although our study is the first investi-gation that demonstrates the positive effects of rosuvastatin on the chemerin levels in patients with AMI, we think that there is a need for further large-scale studies.…”

Section: Discussionmentioning

confidence: 58%

Comparative Effects of Atorvastatin 80 mg and Rosuvastatin 40 mg On The Levels of Serum Endocan, Galectin-3 and Chemerin in Patients With Acute Myocardial Infarction

et al. 2019

View full text Add to dashboard Cite

Comparative effects of atorvastatin 80 mg and rosuvastatin 40 mg on the levels of serum endocan, chemerin, and galectin-3 in patients with acute myocardial infarction Introduction Myocardial infarction remains the leading cause of morbidity and mortality worldwide. In 2015, more than 8.75 million people lost their lives due to coronary artery disease (CAD), accounting for 15.5% of all deaths (1). Endothelial dysfunction, inflammation, and disruption-rupture of atherosclerotic plaques play a critical role in the pathogenesis of atherosclerosis and acute myocardial infarction (AMI) (2-5). Endothelial specific molecule-1 (ESM-1) or endocan, is a soluble dermatan sulfate proteoglycan, secreted and expressed by human vascular endothelial cells (6). The elevated levels of the endocan in patients with tumor progression or in patients with sepsis suggest that endocan may be a probable biomarker for endothelial dysfunction or endothelial activation (7, 8). A previous study showed that endocan levels have been significantly increased in patients with acute coronary syndrome (ACS) (9). In another study, admission endocan levels were found to be associated with in-hospital mortality and the CAD severity index in patients with ST segment elevation myocardial infarction (STEMI) (10). Adipose tissue is an active endocrine organ and regulates energy homeostasis and metabolism by communicating with Objective: Endocan, chemerin, and galectin-3 are discrete biomarkers associated with cardiovascular diseases and acting through different pathophysiological pathways. The aim of this study is to investigate and compare the effects of high doses of atorvastatin and rosuvastatin on serum endocan, chemerin, and galectin-3 levels in patients with acute myocardial infarction (AMI). Methods: Sixty-three patients with AMI were randomized to receive atorvastatin (80 mg/day) or rosuvastatin (40 mg/day) after percutaneous revascularization. Serum levels of endocan, chemerin, and galectin-3 were evaluated at baseline and after 4-week therapy. Results: Endocan levels were not decreased statistically significantly with atorvastatin 80 mg, but rosuvastatin 40 mg markedly decreased the levels of endocan according to baseline [from 110.27 (86.03-143.69) pg/mL to 99.22 (78.30-122.87) pg/mL with atorvastatin 80 mg and from 110.73 (77.28-165.22) pg/mL to 93.40 (70.48-115.13) pg/mL with rosuvastatin 40 mg, p=0.242 for atorvastatin 80 mg and p=0.014 for rosuvastatin 40 mg]. Chemerin levels significantly decreased in both groups according to baseline [from 264.90 (196.00-525.95) ng/mL to 135.00 (105.95-225.65) ng/ mL with atorvastatin 80 mg and from 309.95 (168.87-701.27) ng/mL to 121.25 (86.60-212.65) ng/mL with rosuvastatin 40 mg, p<0.001, respectively, for both groups]. Galectin-3 levels did not change markedly with atorvastatin 80 mg, but they decreased with rosuvastatin 40 mg [from 17.00 (13.10-22.25) ng/mL to 19.30 (15.25-23.45) ng/mL with atorvastatin 80 mg, p=0.721, and from 18.25 (12.82-23.82) ng/mL to 16.60 (10.60-20.15) ng/ mL with rosuvastatin 4...

show abstract

Section: Discussionmentioning

confidence: 58%

Comparative Effects of Atorvastatin 80 mg and Rosuvastatin 40 mg On The Levels of Serum Endocan, Galectin-3 and Chemerin in Patients With Acute Myocardial Infarction

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The following search keywords and terms were used: ((statin * ) or ((“hydroxymethylglutaryl‐CoA reductase”) or (“HMGCoA reductase”) and (inhibitor * )) or (anticholesteremic) or (simvastatin) or (rosuvastatin * ) or (pravastatin * ) or (atorvastatin * ) or (fluvastatin * ) or (cerivastatin * ) or (pitavastatin * ) or (lovastatin * )) and ((ovary) or (ovarian)) and ((cancer) or (neoplasms) or (carcinoma) or (tumor)) and ((prognosis) or (outcome) or (survival) or (mortality) or (recurrence) or (progression) or (metastasis)). In addition, the reference lists of published narrative reviews were scanned to identify potential additional publications not retrieved by the manual search . In an effort to identify unpublished studies, the abstracts of the annual meetings up to 31 December 2017 of the related associations were also manually searched.…”

Section: Methodsmentioning

confidence: 99%

Impact of postdiagnostic statin use on ovarian cancer mortality: A systematic review and meta‐analysis of observational studies

Zhou

2018

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Another important issue is whether the medications for modifying vascular risk factors (e.g., antihypertensive, antihyperlipidemic, and antihyperglycemic agents) can decrease leptin levels. One systematic review for metaanalysis of randomized placebo-controlled trials (RCTs) focused on the impact of statin therapy on plasma leptin levels and showed that results are inconclusive [52]. Another meta-analysis of RCTs investigated the effects of pioglitazone on blood leptin levels in patients with T2DM and showed a significant difference, although relatively few RCTs were included, and a high level of statistical heterogeneity were found.…”

Section: Risk Factors Associated With the Severity Of Canmentioning

confidence: 99%

Associations between adipocytokines and severity of cardiovascular autonomic neuropathy in well-controlled type 2 diabetes and prediabetes

Lai¹,

Chiu²,

Cheng³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background It is thought that adipocytokines contribute to autonomic dysfunction and cardiovascular risks in type 1 and type 2 diabetes mellitus (T1DM and T2DM, respectively). We aimed to identify adipocytokines that are associated with the severity of cardiovascular autonomic neuropathy (CAN) in patients with well-controlled T2DM and prediabetes. Methods The complete cardiovascular autonomic function and biomarkers were assessed for each patient. The severity of CAN was assessed using both the composite autonomic scoring scale (CASS) and the cardiac autonomic reflex tests (CARTs) score. Biomarkers included adipocytokines (leptin, chemerin, adiponectin, and vaspin), oxidative stress (thiols and thiobarbituric acid-reactive substance [TBARS]), endothelial dysfunction (sICAM-1 and sVCAM-1), and insulin resistance (triglyceride/high-density lipoprotein cholesterol [HDL-C] ratio and homeostasis model assessment of insulin resistance [HOMA-IR] index). Results A total of 107 patients were included in this study: 90 with diabetes and 17 with prediabetes. Stepwise logistic regression showed that diabetes duration and leptin level were independently associated with the presence of CAN. Leptin level was positively correlated with body mass index (r = 0.588, P < 0.0001), waist circumference (r = 0.504, P < 0.0001), urinary albumin-to-creatinine ratio (r = 0.351, P = 0.001), hs-CRP (r = 0.291, P = 0.006), TBARS (r = 0.259, P = 0.008), triglyceride/HDL-C ratio (r = 0.346, P < 0.0001), and HOMA-IR index (r = 0.304, P = 0.008) but negatively correlated with thiols (r=-0.25, P = 0.011) level. The leptin level was strongly associated with the CASS (r = 0.36, P < 0.0001) and CARTs (r = 0.356, P < 0.0001) scores. Stepwise linear regression analysis also showed that the leptin level was significantly associated with the CASS and CARTs scores, respectively. Conclusions As the leptin level is considered a prognostic factor in CAN, a longitudinal study is needed to confirm the association between a decrease in obesity and reduced leptin levels and CAN progression.

show abstract

Impact of statin therapy on plasma leptin concentrations: a systematic review and meta‐analysis of randomized placebo‐controlled trials

Abstract: Unless more consistent evidence becomes available in the future, the hypothesis of a relationship between statin use and serum leptin concentrations seem to be unfounded.

Cited by 20 publications

References 54 publications

Comparative Effects of Atorvastatin 80 mg and Rosuvastatin 40 mg On The Levels of Serum Endocan, Galectin-3 and Chemerin in Patients With Acute Myocardial Infarction

Comparative Effects of Atorvastatin 80 mg and Rosuvastatin 40 mg On The Levels of Serum Endocan, Galectin-3 and Chemerin in Patients With Acute Myocardial Infarction

Impact of postdiagnostic statin use on ovarian cancer mortality: A systematic review and meta‐analysis of observational studies

Associations between adipocytokines and severity of cardiovascular autonomic neuropathy in well-controlled type 2 diabetes and prediabetes

Contact Info

Product

Resources

About